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Summary
Prevention of mother-to-child transmission (PMTCT) is essential in HIV/AIDS control. We analysed
2000-05 data from mother-infant pairs in our PMTCT programme in rural Uganda, examining
programme utilization and outcomes, HIV transmission rates and predictors of death or loss to follow-
up (LFU). Out of 19017 women, 1037 (5.5%) attending antenatal care services tested HIV positive. Of
these, 517 (50%) enrolled in the PMTCT programme and gave birth to 567 infants. Before tracing, 303
(53%) mother–infant pairs were LFU. Reasons for dropout were infant death and lack of understanding
of importance of follow-up. Risk of death or LFU was higher among infants with no or incomplete
intrapartum prophylaxis (OR¼1.90, 95% CI 1.07–3.36) and of weaning age <6 months (OR 2.55,
95% CI 1.42–4.58), and lower in infants with diagnosed acute illness (OR 0.30, 95% CI 0.16–0.55).
Mother-to-child HIV cumulative transmission rate was 8.3%, and 15.5% when HIV-related deaths
were considered. Improved tracking of HIV-exposed infants is needed in PMTCT programmes where
access to early infant diagnosis is still limited.
Introduction
By the end of 2007, 480000 women and 130000
children were living with HIV/AIDS in Uganda [1].
In the absence of appropriate interventions to
prevent mother-to-child transmission (MTCT) of
HIV, at least 25% of HIV-exposed children acquire
vertical HIV infection [2].
Guidelines to implement programmes for preven-
tion of mother-to-child transmission (PMTCT)
of HIV are available, but few evaluations of their
effectiveness have been conducted in resource-limited
settings [3–5]. Beyond the difficulties related to
ensuring follow-up and HIV testing of infants in
such settings, little is known about the proportion of
mother–infant pairs that are lost to follow-up (LFU)
after enrolment and the reasons for dropouts [6].
Furthermore, the effectiveness of reducing perinatal
HIV transmission under routine field conditions
has been overestimated, as the substantial numbers
of early dropouts are rarely considered in the
evaluations.
The international medical aid organization
Me ´ decins Sans Frontie ` res (MSF), in collaboration
with the Ministry of Health, provides HIV/AIDS
care in Arua, a rural region in northwestern Uganda.
Arua district has a total population of about 2
million and is near the borders of the Democratic
Republic of Congo and Sudan. MSF also treats HIV-
TB coinfection and supports 10 decentralized health
centres in surrounding areas. The main objectives of
Acknowledgements
The authors would like to thank Dr Robert Downing
and Pr. Christine Rouzioux for performing the
virologic tests and Dr Justine Nakinga and Dr Saul
Onyango of Uganda’s Ministry of Health for
supporting the study and providing the training
material. Also thanks to Dr Jaco Homsy who served
as a scientific advisor and provided precious assis-
tance during the implementation phase of the study
and for the interpretation of findings. We would like
to acknowledge the contribution of the Ministry of
Health and MSF personnel for supporting the study
implementation and providing technical advice.
Special thanks to the participants for sharing their
experiences with us. Finally, we would like to thank
Oliver Yun for editing the paper. This work was
supported by Me ´ decins Sans Frontie ` res.
Correspondence: Laurence Ahoua, Epicentre, 8 rue Saint
Sabin, 75011 Paris, France. Tel.: þ33 1 40 21 28 48.
E-mail: <laurence.ahoua@epicentre.msf.org>.
JOURNAL OF TROPICAL PEDIATRICS, VOL. 56, NO. 1, 2010
 The Author [2009]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 43
doi:10.1093/tropej/fmp054 Advance Access Published on 13 July 2009this study were to quantify the utilization of PMTCT
services in Arua over a 5-year period, describe the
outcomes of mother–infant pairs enrolled in the
programme, determine reasons for programme drop-
outs and identify the predictors of programme losses
after tracing of mother–infant pairs LFU.
Materials and Methodology
Arua PMTCT programme
In 2000, a PMTCT pilot project was initiated by the
Uganda Ministry of Health with the support of MSF
in the Arua Regional Referral Hospital (ARRH) in
northwestern Uganda. Voluntary counselling and
testing (VCT) was offered to all women attending
their first antenatal care (ANC) visit. HIV-infected
women were invited to enrol in the PMTCT
programme and were referred to the HIV/AIDS
clinic for WHO staging and CD4 testing.
The anti-retroviral (ARV) prophylaxis protocol
included the administration of either short-course
zidovudine (sc-AZT) from the 36th week of preg-
nancy to the mothers and in the first week of life to
their newborns, or single-dose nevirapine (sd-NVP)
at the onset of labour or at least 2h before delivery to
the mothers and within 72h after birth to their
newborns. For women in need of ARV therapy
(ART), an NVP-containing regimen was adminis-
tered following international recommendations [7].
At antenatal care, mothers were encouraged to
deliver at the hospital, but also received NVP
prophylaxis for them and their babies in the event
of home delivery.
After delivery, clinical examination and feeding
counselling were provided at weeks 1, 6, 10 and 14,
then every 3 months up to 18 months post-partum.
Infant formula was provided free of charge up to
June 2004, but exclusive breastfeeding was advised
thereafter because most of the mothers who received
infant formula had been practicing mixed feeding
even though it had always been counselled against.
The HIV serostatus of the infants was determined at
18 months of age using two serological rapid tests.
Study design and procedures
We retrospectively analysed the information of
all mother–infant pairs enrolled in the PMTCT
programme in Arua between July 2000 and July
2005. LFU pairs were those with unknown infant
HIV status at 18 months of age and who had missed
their last scheduled appointment for  2 months
before the start of the study. After active tracing
of the mother–infant pairs who had been LFU,
we conducted a cross-sectional survey to determine
the clinical–immunological and HIV status of the
children alive, and investigated the reasons for
care discontinuation. The tracing took place in all
neighbouring health facilities and at the patients’
home. To preserve patient confidentiality, the study
team members introduced themselves as hospital
nurses who were providing routine health care to
mothers and their babies. The mothers were invited
to attend the nearest health facility where the study
objectives and procedures were explained. They were
free to accept or decline the invitation. For those who
agreed to participate, a written informed consent was
obtained and study procedures were initiated.
For children not yet tested, VCT and HIV testing
were proposed. HIV infection was diagnosed by
two positive rapid serological HIV 1/2 tests for the
children aged  18 months (Determine, Abbott
Diagnostic Division, Hoofddorp, the Netherlands;
and Statpack, Chembio Diagnostic Systems,
Medford, NY, USA) or by DNA PCR tests if aged
<18 months (Amplicor HIV-1 Monitor Test, v1.5,
Roche Diagnostic Systems, Indianapolis, IN, USA).
Data collection and analysis
Data on HIV diagnosis, ART history, PMTCT
enrolment, delivery and follow-up outcomes were
extracted from medical records. A standardized pre-
tested questionnaire, which had been back-translated
into the local languages Lugbara, Kiswahili, Kakwa
and Alur, was administered during the cross-
sectional survey to complete missing PMTCT
follow-up information and collect reasons for LFU.
Compliance to the PMTCT protocol was evaluated
only among mother–infant pairs who received NVP
prophylaxis [8, 9] or ART (information on adherence
related to sc-AZT had not been recorded). Mothers’
compliance to the PMTCT protocol was defined
as follows: ‘fully’ (on ART at the time of delivery, or
sd-NVP taken at the onset of contractions and at
least 2h before delivery); ‘moderately’ (sd-NVP taken
before the onset of contractions and 2–7h before
delivery); ‘non compliant’ (no ART and no sd-NVP
prophylaxis taken at the time of delivery or sd-NVP
taken either within 2h of delivery or  7h before
delivery). Infants’ compliance was defined as follows:
‘fully’ (received NVP within 72h of birth); ‘moder-
ately’ (received NVP between 72h and 7 days after
birth); and ‘non compliant’ (did not receive ARV
prophylaxis or received NVP >7 days after birth).
Standard WHO definitions were used to define
breastfeeding, replacement feeding or mixed feeding
[10, 11]. For children who died before testing,
probable HIV infection was assessed through verbal
autopsy using the definition proposed by the Ghent
International Working Group [12].
We used Kaplan–Meier methods to estimate the
probabilities of completing follow-up in the PMTCT
programme by 18 months post-partum, after exclud-
ing stillbirths. The follow-up time was right-censored
at the date of the confirmatory HIV test for infants
tested before or at 18 months of age, of death
for those who died before HIV testing, of the last
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age and at 18 months for other infants. We used
multiple logistic regression, allowing for clustering by
mother–infant pairs to assess risk of LFU or death.
All variables associated with the outcome in uni-
variate analyses (Wald p-value <0.25) were included
in the multivariable model. A backward-stepwise
strategy was then applied to obtain the final model.
Statistical analyses were performed using Stata 9.2
(Stata Corp., College Station, TX, USA).
The study was approved by the Ugandan National
Council for Science and Technology, the Ugandan
AIDS Research Committee and the Ethics
Committee of Saint-Germain-en-Laye (France).
Results
Study population
Of the 30536 women who attended their first ANC
visit between July 2000 and July 2005, 19017 (62%)
underwent counselling and HIV testing (Fig. 1). Five
per cent (1037/19017) of these women were HIV
positive, and 517 (50%) of the 1037 agreed to enrol in
the PMTCT programme. A total of 567 infants were
born from the women enrolled. Before tracing,
303/567 (53.4%) mother–infant pairs had been
LFU, 89 (15.7%) were followed, 97 (17.1%) children
had died and 78 (13.8%) had completed their follow-
up and the child had been tested for HIV. After
active tracing, outcome data from 327 women and
368 babies were available and analysed.
Mother characteristics
Of the 327 HIV-positive women analysed, 71.3%
(233/327) enrolled during their third trimester of
pregnancy, and their median age was 28 years (IQR
25–32). A total of 164 (50.2%) women were in
clinical Stage 1 or 2, and the median CD4 cell count
was 368 cells/mm
3 (n¼201; IQR 200–535) (Table 1).
Of the 100 (30.6%) women eligible for ART at
enrolment but not yet on therapy, 19 started ART
before delivery, 47 after delivery and 34 never
received ART.
A total of 242 (74.0%) women delivered at the
hospital and 68 (20.8%) at home or on the way to the
hospital. At delivery, 227 (69.4%) women received
intrapartum sd-NVP, 17 (5.2%) sc-AZT, 23 (7%) did
not take any prophylaxis and 52 (15.9%) had been on
ART for a median time of 6.7 months (IQR 2.0–15.4)
prior to delivery (Table 1). Of those receiving ART or
intrapartum sd-NVP (n¼302), 205 (67.9%) were
fully, 5 (1.6%) moderately and 92 (30.5%) not
compliant with the PMTCT protocol.
At discharge from the PMTCT programme or at
the last recorded visit, 91% of the women had
disclosed their HIV status to their partner. Further-
more, 74% reported that their partners were aware of
their attendance to the PMTCT programme and that
this had not caused any family conflict.
Infant characteristics
Of the 368 infants, 8 (2.2%) were stillborn and
7 (1.9%) died within 24h of birth. Of the 353 infants
alive, 288 (81.6%) received sd-NVP, 12 (3.4%)
sc-AZT and 50 (14.2%) did not receive post-partum
ARV prophylaxis (Table 2). Among those receiving
sd-NVP or no ARV prophylaxis (n¼338), 282
(83.4%) were fully, 3 (0.9%) moderately and
53 (15.7%) non-compliant with the PMTCT proto-
col. Of the 353 babies alive, 47 (13.3%) were
exclusively breastfed, 96 (27.2%) received replace-
ment feeding and 210 (59.5%) were mixed fed.
Median age at start of weaning was 6 months (IQR
4–6), irrespective of the type of feeding (p¼0.15).
At least one serious acute illness, namely acute
respiratory tract infection (RTI), malaria or diar-
rhoea, was reported during the follow-up in 70%
of infants.
Of the 72 children who died during follow-up
(excluding stillborn), 33 (45.8%) died of HIV-related
causes. The most frequently reported HIV-related
events were diarrhoea (34.7%), RTI (20.8%), candi-
diasis (13.9%) and bacterial infection or septicaemia
(11.1%).
Overall, 367 children had been tested for HIV.
Cumulative HIV transmission rate was 8.3% (24/288,
95% CI 5.6–12.2) among infants tested, and 15.5%
(57/367, 95% CI 12.2–19.6) when probable HIV-
related deaths were included. Transmission rates did
not differ by type of feeding (19.2, 10.5 and 18.1%
for exclusive breastfeeding, replacement feeding
and mixed feeding, respectively; Pearson  
2 test,
p¼0.20).
Lost to follow-up mother–infant pair outcomes
Overall, 303/567 (53.4%) mother–infant pairs had
been LFU after a median time of 1 month (IQR 0–5).
Of the 197 pairs successfully traced, 45 (22.8%) had
been LFU after PMTCT enrolment, 2 (1%) between
enrolment and delivery, 42 (21.3%) after delivery
and 108 (54.8%) during follow-up. Main reasons
for dropping out were the mothers’ lack of under-
standing of the importance of follow-up (29.9%)
and infant death (27.4%) (Table 3). Probability of
completing PMTCT follow-up by 18 months post-
partum was 0.50 (95% CI 0.44–0.55) (Fig. 2).
Risk of LFU or death was decreased in children
with recorded episodes of acute infection during their
follow-up (OR 0.30; 95% CI 0.16–0.55). In contrast,
risk was higher in infants who started weaning before
the age of 6 months than in those who started later
(OR 2.55; 95% CI 1.42–4.58), and in infants who
breastfed for >6 months than in those who breastfed
for<6months(OR4.40;95%CI2.00–9.65)(Table4).
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￿ Incomplete/missing address (n = 110)
￿ Refusal to participate (n =10) 





￿ Infant deaths = 80 (22%)
￿ Follow-up completed = 288 (78%)
Mother/infant pairs’ outcomes 
n=567 
￿ Lost to follow-up = 303 (53%) 
￿ Actively followed = 89 (16%) 
￿ Infant deaths = 97 (17%) 
￿ Follow-up completed = 78 (14%) 
First antenatal care visit 
(July 2000 – July 2005) 
n=30,536 
Pre-test HIV counselling 
n=22,105 (72%) 








Mothers enrolled in PMTCT 
n=517 (50%) 
PMTCT enrolment refused 
n=520 (50%) 
Final outcomes after tracing 
n=567 
￿ Lost to follow-up = 174 (30%) 
￿ Infant deaths = 101 (18%) 
￿ Follow-up completed* = 292 (52%) 
FIG. 1. Diagram of mother–infant pairs included in the study, Arua, March 2006.
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Characteristics of infants at birth and last PMTCT
follow-up, Arua, March 2006
Infant characteristics Total
(n¼368)
Females, n (%) 182 (49.5)
Weight at birth (kg) (n¼334),
median (IQR)
3 (2.7–3.4)
Vital status at birth, n (%)
Alive 360 (97.8)
Stillborn 8 (2.2)
Prematurity at birth, n (%) 15 (4.1)
Death within 24h after birth, n (%) 7 (1.9)
Vital status at hospital discharge, n (%)
Alive and well 351 (95.4)
Alive with problems 2 (0.5)
Dead 15 (4.1)
Timing of mother ARV use, n (%)
ART initiated  3 months before birth 44 (12.0)
ART initiated <3 months before birth 21 (5.7)
ARV intrapartum prophylaxis 272 (73.9)
No intrapartum medication taken 24 (6.5)
Unknown 7 (1.9)
Type of infant ARV prophylaxis after
birth
a (n¼353) n (%)
NVP 288 (81.6)
AZT 12 (3.4)
Not given 50 (14.2)
Unknown 3 (0.8)
Number of PMTCT visits, median (IQR) 7 (3–12)
Pre-natal visits 3 (1–4)
Post-natal visits 4 (0–8.5)
Number of immunization visits, n (%)
No visits 16 (4.3)
1–3 visits 30 (8.1)
4–6 visits 285 (77.5)
 7 visits 30 (8.2)
Unknown 7 (1.9)




Type of care giver at last visit, n (%)
Mother 361 (98.1)
Father/other family member 7 (1.9)
Type of feeding received during
follow-up (n¼353), n (%)
Exclusive breastfeeding 47 (13.3)
Replacement feeding 96 (27.2)
Mixed feeding 210 (59.5)
Duration of breastfeeding
a,b
(months) (n¼353), median (IQR)
3 (0–6)




Infant follow-up outcome, n (%)
Death
c 80 (21.7)
HIV tested before survey 75 (20.4)
HIV tested during survey 213 (57.9)
aAmong babies born alive only.
bRegardless of the type of feeding (i.e. exclusive or mixed
feeding).
cIncluding 8 stillborns, 7 deaths <24h after birth and 65
deaths during post-partum follow-up.
ARV, anti-retroviral; AZT, zidovudine; IQR, interquar-
tile range; NVP, nevirapine.
TABLE 1
Characteristics of mothers at PMTCT enrolment and
delivery, Arua, March 2006
Total
(n¼327)
Mother characteristics at enrolment
Age (years), median (IQR) 28 (25–32)
Number of gestations, median (IQR) 4 (2–6)




At/after birth 18 (5.5)
ARV history, n (%)
ARV naive 294 (89.9)
ARV non-naive 33 (10.1)
On ART 32
Other 1
WHO stage (n¼326), n (%)
Asymptomatic 5 (1.5)
Stage 1/2 164 (50.2)
Stage 3 144 (44.0)









 500 56 (27.8)
Perception of counselling received, n (%)
Clear and supportive 314 (96.0)
Not clear and/or supportive 13 (4.0)
Mother characteristics at delivery
Place of delivery, n (%)
Arua Regional Referral Hospital 242 (74.0)
Home/on the way to hospital 68 (20.8)
Health centre/other hospital 16 (4.9)
Other 1 (0.3)
Type of delivery, n (%)
Normal/assisted vaginal 292 (89.3)
Caesarean section 30 (9.2)
Other 3 (0.9)
Unknown 2 (0.6)
Delivery complications, n (%) 40 (12.2)
Premature labour, n (%) 12 (3.7)
Type of intrapartum ARV received, n (%)
Not taken 23 (7.0)
Single dose NVP 227 (69.4)




ARV, anti-retroviral; AZT, zidovudine; IQR, interquar-
tile range; NVP, nevirapine.
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In this evaluation of a PMTCT programme in rural
Uganda, only half of the women tested HIV-positive
agreed to attend PMTCT services and more than 5 in
10 mother–infant pairs were lost to follow-up. The
low PMTCT uptake observed in our study is similar
to that previously reported in Ethiopia (57%) and
Zimbabwe (59%), but higher than in Kenya (17%)
[13]. It is, therefore, essential to intensify efforts to
improve programme uptake to ensure optimal access
to ARV prophylaxis for women who are in need.
Women’s characteristics at enrolment were similar
to those described in other resource-limited settings
[14, 15]. Thus, 7 in 10 women were enrolled during
their third trimester of pregnancy and 5 in 10at early
stage of HIV disease. The proportion of hospital
deliveries was high, probably because the maternity
ward was rehabilitated in 1999 and improved access
to health care for deliveries. Still, 20% of women
delivered at home. Half of the women who entered
the programme were eligible for ART. Yet, only 16%
were on ART at time of delivery, and 7% did not
receive any prophylaxis or treatment.
These results highlight the importance of identify-
ing women eligible for ART early in their pregnancy
in order to initiate treatment, as high maternal
viraemia is the most important risk factor for
perinatal HIV transmission [16]. They also show the
existence of missed opportunities for the timely
provision of health care to HIV-infected patients
and stress the need to strengthen the links between
the PMTCT and HIV care services. Despite the
simplicity of the protocols used, 30% of women and
16% of newborns did not comply with the protocol.
The effectiveness of the PMTCT prophylaxis to
prevent perinatal HIV transmission requires that
both mother and infant correctly take the drugs.
Maternal dosing alone would fail to achieve pro-
longed infant prophylactic drug concentrations,
especially if the time between ingestion and delivery
is short [17]; and infant dosing alone has modest, if
any, prophylactic efficacy [18].
In our cohort, women were given the choice
between using exclusive free infant formula or
exclusive breastfeeding, but our assessment showed
that  60% of children were mixed fed, reflecting the
difficulties that HIV-positive mothers find to adhere
to their initial feeding choice in rural Uganda as well
as the confusing nature of the counselling messages
related to infant feeding given at that time. The most
appropriate infant-feeding practice for PMTCT in
resource-limited settings is still highly debated [19].
Exclusive breastfeeding offers the best possible nutri-
tionaloptionduringthefirstmonthsoflife,protecting
children against diarrhoea and lower RTI, which
are the leading causes of infant mortality [20, 21].
Nevertheless, the cumulative probability of late
TABLE 3
Timing and reasons for PMTCT dropout of mother–infant pairs lost to follow-up, Arua, March 2006
Mother–infant pairs Included, n¼197 Excluded, n¼175 p-value
Geographical residence, n (%)
Arua Municipality Council 89 (45.2) 86 (49.1) <0.0001
Ayivu county 72 (36.6) 40 (22.9)
Other Arua counties 24 (12.2) 13 (7.4)
Other 12 (6.0) 36 (20.6)
Year of PMTCT enrolment, n (%)
 2002 27 (13.7) 51 (29.1) 0.001
2003 41 (20.8) 43 (24.6)
2004 67 (34.0) 42 (24.0)
2005 62 (31.5) 39 (22.3)
Duration of follow-up, median (IQR) 2.9 (0.1–7.7) 0.5 (0–3.4) <0.0001
Time of LFU, n (%)
At enrolment in PMTCT programme 45 (22.8) 60 (34.3) 0.08
Between enrolment and birth 2 (1.0) 1 (0.6)
At the time of birth 42 (21.3) 38 (21.7)
During follow-up 108 (54.8) 76 (43.4)
Reasons for LFU, n (%)
Maternal illness/death 6 (3.1) N/A N/A
Infant death 54 (27.4)
Lack of partner involvement 26 (13.2)
Moved away 24 (12.2)
Lack of understanding of follow-up benefit 59 (29.9)
Fear of stigma 12 (6.1)
Other 16 (8.1)
LFU, lost to follow-up; IQR, interquartile range.
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breastfed children [22]. In certain settings, opting for
formula feeding has been shown to be feasible when
individual and environmental criteria are used [23].
Infant formula in combination with a single oral
dose cabergoline, a long-lasting dopaminergic drug
with prolactin inhibitory properties, can be effec-
tively used to avoid mixed feeding [24, 25].
However, in most rural African settings, replace-
ment feeding might not be feasible due to social
and cultural pressure and to poor hygiene [26, 27],
and mixed feeding is in practice the most prevalent
mode of feeding among those opting for infant
formula. Given that mixed feeding increases the
likelihood of HIV transmission, a large proportion of
the infants in our cohort were exposed to HIV
infection during the postnatal period despite good
compliance with PMTCT protocols. Effective inter-
ventions to reduce postnatal HIV transmission during
breastfeeding, such as providing ART to the mother
during the first 6 months after delivery, are some of
the strategies that have been evaluated [28].
Twenty-two per cent of the children died before
HIV testing, and diarrhoea accounted for more than
a third of the deaths. Similar figures were reported in
a study in Co ˆ te d’Ivoire, where 18% of the infant
deaths were attributed to diarrhoea [29]. In this
study, the cumulative HIV transmission rate was
8% among children tested up to 18-months of age
and increased to 16% when probable HIV-related
deaths were considered. In the absence of tracing, we
would have estimated an HIV transmission rate of
4%, knowing that 53% of mother–infant pairs had
been LFU. This illustrates how high LFU rates can
bias programme estimates of HIV transmission and
corroborates previous reports showing how HIV
transmission can be seriously underestimated when
routine data are used [6, 30].
Most women defined the counselling provided at
enrolment as clear and supportive. However, half of
the mother–infant pairs were LFU before determina-
tion of the child’s HIV status. Previous studies have
also reported high LFU rates in routine PMTCT
services. In rural Malawi, the LFU rate was 81% by
6 months of postnatal follow-up [6]. In South Africa,
despite reported high rates of NVP administration
and good acceptance of infant formula, >70% of
infants were LFU by 4 months of age [5]. Also, in our
study, nearly 37% of mothers traced could not be
found. This finding highlights the difficulties with
tracing in retrospect instead of using active defaulter
tracing, since many women might have moved to
FIG. 2. Probabilities of mother–infant pairs completing follow-up by 18 months postpartum, Arua, March 2006
(n¼360).
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Republic of Congo.
In our cohort, the main reasons for dropping out
were the lack of understanding of the importance
of follow-up and infant death. Absence of partner
involvement and stigma were the reasons that were
less frequently reported. Reasons for dropout are
likely to differ by the type of PMTCT service
provided and by the sociocultural context. In
Botswana, the main reasons reported were poor
acceptability of infant formula and the fear of HIV
disclosure [31]. Others have reported negative
experience with the health staff or negative percep-
tion of the PMTCT programme [32]. In our setting,
earlier age of weaning, prolonged breastfeeding and
incomplete/absent ARV prophylaxis were associated
with an increased risk of LFU or death, while the
occurrence of infant acute illness decreased this risk.
This suggests that in the absence of infant illness,
mothers do not perceive the need to seek medical
care and stresses the necessity of improving the
quality of the information provided to the mothers
TABLE 4
Associations between lost to follow-up or death and maternal and infant factors, Arua, March 2006
OR
n (%) N Crude 95% CI p-value Adjusted
a 95% CI p-value
Maternal factors
Trimester of pregnancy at enrolment
Third or after delivery 150 (54.3) 276 1 0.95 1 0.09
First or second 46 (54.7) 84 1.02 0.62–1.66 1.81 0.91–3.60
Enrolment in Arua hospital
Yes 159 (51.3) 310 1 0.005 1 0.20
No 37 (74.0) 50 2.70 1.35–5.41 1.90 0.72–5.06
Number of previous gestations
<4 91 (60.7) 150 1 0.08 1 0.20
 4 104 (51.0) 204 0.67 0.43–1.05 0.67 0.36–1.23
Clinical stage at enrolment
1 or 2 108 (60.0) 180 1 0.43–0.98 0.04 1 0.39–1.15 0.15
3 or 4 88 (49.2) 179 0.64 0.67
Partner disclosure of PMTCT attendance
No 57 (57.6) 99 1 0.47 1 0.91
Yes 139 (53.3) 261 0.84 0.52–1.35 0.96 0.51–1.83
Paternal factors
Occupation of the father
None/farmer 24 (61.5) 39 1 0.04 1 0.39
Businessman 46 (69.7) 66 1.44 0.61–3.40 1.67 0.56–4.99
Employee 48 (49.0) 98 0.60 0.27–1.33 1.04 0.39–2.79
Unemployed/other 77 (51.0) 151 0.65 0.31–1.38 0.80 0.33–1.97
Infant factors
RV intrapartum prophylaxis
Complete (mother and child) 62 (82.7) 75 1 0.08 1 0.03
None or incomplete 134 (47.0) 285 1.56 0.95–2.55 1.90 1.07–3.36
Type of feeding
Exclusive breastfeeding 26 (55.3) 47 1 0.02 1 0.83
Replacement feeding 40 (41.7) 96 0.58 0.28–1.18 0.89 0.30–2.60
Mixed feeding 123 (58.6) 210 1.14 0.61–2.15 0.76 0.28–2.07
Duration of breastfeeding
0–5.9 months 129 (46.2) 279 1 <0.0001 1 0.0002
 6 months 60 (81.1) 74 4.98 2.65–9.37 4.40 2.00–9.65
Age at start of weaning
 6 months 91 (42.5) 214 1 <0.0001 1 0.002
<6 months 98 (70.5) 139 3.23 2.06–5.07 2.55 1.42–4.58
Recorded acute illness
b
No 168 (62.7) 268 1 <0.0001 1 0.0001
Yes 28 (30.4) 92 0.25 0.16–0.41 0.30 0.16–0.55
aRatios from multiple logistic regression allowing for clustering by mother–infant pairs and adjusted for all other variables
except partner disclosure.
bIncludes episodes of malaria, lower respiratory tract infections and diarrhoea.
CI, confidence interval; OR, odds ratio.
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follow-up.
Due to logistic and financial constraints, we
focused our tracing on mother–infant pairs living in
the Arua district, and we cannot generalize the
findings to those residing outside this area. Pairs not
traced were more frequently LFU shortly after
PMTCT enrolment and in the early years of the
programme. Although ensuring patient confidenti-
ality was challenging, women were free to particip-
ate or not in the study. Most of them accepted
(10 patients declined participation). They also
expressed their appreciation to have the opportunity
to discuss freely their experience with the study team.
Because the exact age of infection was unknown
for most infants, we could not estimate the infants’
HIV-free survival. Nevertheless, our estimates can
be reported as a proportion of the total number of
infants tested [33]. Finally, we corrected HIV
transmission rates by including probable HIV-related
deaths in the calculation. The cause of death was
ascertained through verbal autopsy [12] and, there-
fore, it is possible that some have been misclassified
as being related or not to HIV infection, resulting in
underestimation or overestimation of the transmis-
sion rates.
Our results reflect the day-to-day difficulties faced
by PMTCT programmes in rural, resource-limited
settings, which are far more challenging than those
observed in the context of clinical trials or ‘model
programme’ settings. The effectiveness of PMTCT
programmes depends on a cascade of interventions,
the adequate provision of an effective ARV prophy-
laxis being only one of them. Increasing ART
coverage for women in need, better tracking and
follow-up of HIV-exposed infants and an enhanced
quality of infant feeding counselling are all essential
to improve PMTCT effectiveness in rural Africa.
Current recommended strategies include short-course
AZTþ3TCþNVP in pregnant women with HIV
(from 28 weeks of pregnancy or as soon as possible
thereafter), ART for life in all mothers with CD4
count <350 cells/mm
3 at time of programme entry,
and immediate ART start in HIV-positive newborns
[34–36]. Such strategies will help achieve the goals for
paediatric AIDS control to reduce vertical transmis-
sion by 50% and provide PMTCT services to 80% of
those in need by 2010 [37].
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